

1 Vendor Selection and Management

2 Sachi Amatya, MBA, EdD, CCDM^a Dawn Edgerton, MBA, RAC^b

3 a: Shire, Lexington, MA; b: Edgerton Data Consulting, LLC Chapel Hill NC;

4 1) Abstract

5 Vendors provide services that are critical to the successful outcome of a clinical study, yet
6 sponsors retain the ultimate responsibility for activities that are outsourced. Thus, if a
7 sponsor delegates study activities to a vendor or a vendor's vendor and so on, the sponsor
8 should take measures to ensure the vendor and any subcontractors are consistently
9 delivering products or services of acceptable quality. This chapter provides
10 recommendations for evaluating, selecting, and providing oversight of vendors to determine
11 whether their services adequately meet Sponsor expectations including quality requirements
12 and regulatory standards.

13 After reading this chapter, the reader should understand:

- 14 • The purpose of and regulatory basis for vendor selection and management
- 15 • Differences in outsourcing and contracting models
- 16 • Processes for vendor selection
- 17 • Contents and organization of a vendor scope of work (SOW)
- 18 • Processes for vendor oversight
- 19 • Governance models for strategic partnerships

20 2) Introduction

21 In the mid to late 1990s outsourcing in clinical studies, in particular clinical trials, saw
22 significant increases. Today, vendors are used in all aspects of clinical studies and have
23 particular relevance in clinical data management (CDM) processes. Examples of vendors
24 relevant to CDM include contract research organizations (CROs), electronic patient reporting
25 tool providers, clinical laboratories, specialty labs, central readers, imaging vendors,
26 pharmacokinetics (PK) vendors, immunogenicity vendors, interactive web/voice response
27 system (IxRS) providers, electronic data capture (EDC) and other software suppliers, and off-
28 site storage and data hosting facilities. Before a vendor is selected, the deliverable or result
29 desired from the vendor should be clearly defined and described.

30 Title 21 CFR Part 312 Responsibilities of Sponsors and Investigators requires official transfer
31 obligations to a Contract Research Organization (CRO). (Title 21 CFR 312.52) Therefore, CROs
32 should expect sponsors' oversight and should be prepared to perform vendor oversight for
33 responsibilities the CRO contracts to others. Regulation and guidance are clear that
34 "Ultimate responsibility for the quality and integrity of the trial data always resides with the
35 sponsor." (ICH E6(R1 5.0)) Thus, sponsors must manage vendors and the vendors of vendors
36 in a way that ensures quality, integrity, and reliability.

37 **3) Scope**

38 The scope of vendor services differs widely across the industry, ranging from protocol
39 development to assistance with a regulatory submission. This chapter examines the
40 communication of clear expectations between the vendor and the sponsor and some
41 strategies for clearly documenting various areas of vendor oversight. The chapter also
42 includes considerations for vendor qualification and the appropriate level of oversight
43 needed, depending on the vendor's scope of work and risks identified. Details and
44 discussions regarding relationship management are beyond the scope of this chapter.

45 Disciplines such as operations engineering have developed methods for assuring quality of
46 goods and services. These have been encoded into standards for Quality Management
47 Systems through the International Organization for Standardization (ISO) and maturity
48 models for such systems through the Software Engineering Institute (SEI). In project driven
49 industries like therapeutic development, Quality Management Systems rely in part and
50 heavily on project management to plan and manage work within and across organizations to
51 successful conclusion. (Project Management Institute 2013) The Project Management
52 Institute has developed and currently maintains the Project Management Body of
53 Knowledge (PMBOK) and a professional certification program for project management.
54 Project management fundamentals are not covered here. This chapter instead focuses on
55 Data Management-relevant content for common project management tools. These methods
56 and practices together are foundational to managing the "quality throughout all stages of
57 the trial process" and "ensuring human subject protection and the reliability of trial results."
58 (ICH E6 section 5.0 2018)

59 Some of the tasks described in this chapter may be joint responsibilities among or performed
60 by different groups. However, clinical data managers must be knowledgeable about
61 performance of tasks relevant to data quality and integrity.

62 **4) Minimum Standards**

63 Both regulation and guidance address transfer of Sponsor obligations. In particular, the
64 United States Code of Federal Regulations Title 21, subpart D, Part 312 states the following:

65 *Part 312.52* Transfer of obligations to a contract research organization states, "(a) A
66 sponsor may transfer responsibility for any or all of the obligations set forth in this part to a
67 contract research organization. Any such transfer shall be described in writing. If not all
68 obligations are transferred, the writing is required to describe each of the obligations being
69 assumed by the contract research organization. If all obligations are transferred, a general
70 statement that all obligations have been transferred is acceptable. Any obligation not
71 covered by the written description shall be deemed not to have been transferred." And that,
72 "(b) A contract research organization that assumes any obligation of a sponsor shall comply
73 with the specific regulations in this chapter applicable to this obligation and shall be subject
74 to the same regulatory action as a sponsor for failure to comply with any obligation assumed

75 under these regulations. Thus, all references to “sponsor” in this part apply to a contract
76 research organization to the extent that it assumes one or more obligations of the sponsor.”

77 The International Council for Harmonization E6(R2) Good Clinical Practice: Integrated
78 Addendum to ICH E6(R1) Guidance for Industry (ICH E6(R2)) further elaborates on transfer of
79 obligations.

80 Section 5.0 states that, “The sponsor should implement a system to manage quality
81 throughout all stages of the trial process.” Section 5.0.1 goes on to specify that, “During
82 protocol development the Sponsor should identify processes and data that are critical to
83 ensure human subject protection and the reliability of trial results.”

84 Section 5.0.2 describes risk identification, evaluation, control, communication, review, and
85 reporting with section 5.0.2 stating that, “The sponsor should identify risks to critical trial
86 processes and data. Risks should be considered at both the system level (e.g., standard
87 operating procedures, computerized systems, personnel) and clinical trial level (e.g., trial
88 design, data collection, informed consent process).”

89 Section 5.2.1 echoes 21CFR312.52 stating that, “A sponsor may transfer any or all of the
90 sponsor’s trial-related duties and functions to a CRO” and further adds that, “the ultimate
91 responsibility for the quality and integrity of the trial data always resides with the sponsor”
92 and that, “The CRO should implement quality assurance and control.”

93 Section 5.2.2 specifies that, “Any trial-related duty and function that is transferred to and
94 assumed by a CRO should be specified in writing.”

95 The addendum in section 5.2 states that, “The sponsor should ensure oversight of any trial-
96 related duties and functions carried out on its behalf, including trial-related duties and
97 functions that are subcontracted to another party by the sponsor’s contracted CRO(s).” With
98 section 5.2.3 stating that, “Any trial-related duties and functions not specifically transferred
99 to and assumed by a CRO are retained by the sponsor.” Similarly, ICH E6(R2), section 5.2.4
100 echoes 21, subpart D, Part 312(b), stating, “All references to a sponsor in this guidance also
101 apply to a CRO to the extent that a CRO has assumed the trial-related duties and functions of
102 a sponsor.”

103 Thus, with respect to selection and management of vendors, we state the following as
104 minimum standards:

- 105 • Sponsors should assess a vendor’s Quality Management System and deem it
106 appropriate prior to receiving goods or services toward a clinical study.
- 107 • Decisions made in the course of such an assessment may be risk-based.
- 108 • Sponsors should assess potential impact of contracted work on human subject
109 protection and reliability of trial results.
- 110 • Sponsor responsibilities delegated to a vendor should be documented in writing.
- 111 • Sponsors should establish a vendor-auditing program including plans to and criteria
112 for re-audit.

- 113 • Sponsors who contract goods or services toward a clinical study should provide
114 adequate oversight.

115 5) Best Practices

- 116 • Obtain a confidentiality agreement with the vendor prior to exchange of proprietary
117 information. [VI]
- 118 • Document the sponsor's process and support functions needed to evaluate the use of
119 vendor services. [VI]
- 120 • Evaluate and qualify, e.g., by capacity, capability, qualifications, experience,
121 regulatory compliance, company stability, vendors prior to contracting for their
122 services or products. [VI]
- 123 • Create a contacts list that is centrally accessible to study team members. [VI]
- 124 • Determine and document whether the sponsor's, the vendor's, or a combination
125 thereof standard operating procedures (SOPs) are to be followed. [VI]
- 126 • Clearly define expectations, deliverables, and responsibilities. [III] (PMI 2013) Both
127 the sponsor and the vendor must participate in defining expectations, deliverables
128 and responsibilities. [VI]
- 129 • Conduct ongoing management of vendor activities by communicating and assessing
130 the vendor's performance throughout the study. [III] (PMI 2013)
- 131 • Review data transfer agreement for all the third party vendors. [VI]
- 132 • Where feasible, evaluate from a CDM perspective the risk of utilizing or not utilizing
133 vendor services related to the conduct and outcome of the study. [VI]
- 134 • Maintain an internally approved vendor list (Template available in Appendix A) with
135 regular evaluations (e.g., preferred vendor list or prequalified vendor list). This may
136 be risk-based. [VI]
- 137 • The vendor-auditing program should be cross-functional based on contracted
138 services. [VI]
- 139 • Processes for vendor evaluation, vendor audits, issue resolution, and escalation
140 should be informed by cross-functional subject matter experts within a centralized
141 organizational team. Use a subject matter consultant if your organization lacks this
142 expertise in-house. [VI]
- 143 • Define and document a detailed statement of work and project plans that delineate
144 each task, role or person responsible, task timing and dependencies, related
145 documentation, role or person responsible for reviewing and approving related
146 documentation or other task results, and reporting related to the task. [VI]
- 147 • Define and document detailed sponsor/vendor communication plans that clearly
148 address the expected communication tools and frequency, as well as establish who is
149 responsible for communications and how to escalate issues when deemed necessary.
150 [VI]
- 151 • In high risk situations, identify other possible vendors or options as part of a
152 contingency plan in case the vendor relationship is deemed unsatisfactory at any
153 point during the course of the study. [VI]

- 154 • Establish a collaborative relationship based on partnership, trust, and coownership of
155 the project. [VI]
- 156 • Hold frequent one-on-one meetings or teleconferences with the vendor lead to share
157 concerns, provide mutual feedback, plan for success, and ensure activities are on
158 track without any red flags. [VI]
- 159 • If the vendor is providing services that involve computerized systems, ensure system
160 support documentation is in place. For example, establish a service level agreement
161 (SLA), that describes in detail how much time it will take the vendor to respond to
162 support inquiries, how long it will take to get a database back online in case of a
163 system failure, and other details related to supporting the sponsor’s business
164 requirements. [VI]
- 165 • Study teams should engage early to begin a study-level sourcing strategy and vendor
166 identification. [VI]
- 167 • SLAs should be defined for vendors with whom your organization works frequently.
168 [VI]

169 **6) Types of Vendors and Vendor Services Commonly Used in CDM**

170 Required vendor services will vary from study to study depending on the needs of the study
171 and resources already available within the organization. Below are some of the key types of
172 vendors often utilized during the course of a clinical study:

173 *a) Contract Research Organization (CRO)*

174 Over the past several decades, CROs have gradually evolved from organizations providing
175 limited services in clinical trial management into organizations that have expertise across
176 a wide spectrum of the clinical development process. Today, CROs provide a broad
177 spectrum of services, from full service contracts to only data management services.

178 A full service contract would include a wide range of services from a single CRO, such as
179 study management, site monitoring, data management, biostatistics, or medical writing.
180 The Sponsor determines the services needed and CROs respond with a plan for meeting
181 those requirements. Multiple CROs might propose different services for their
182 participation in a study. For example, if the contract is for data management only, some
183 CROs might choose to conduct all aspects of data management in-house while others
184 might not. Some types of services included by CROs providing data management services
185 include:

- 186 • Data Management (DM) project management
- 187 • Development of electronic case report form (eCRF) specification based on protocol
188 needs
- 189 • Development of paper case report form for additional data collection if required by
190 the protocol. For example, adjudication committee, medical review by a third party
191 specialist, etc.
- 192 • Creation of Case report form (CRF) completion guidelines

- 193 • Creation of the data management plan (DMP) or equivalent documentation
- 194 • Database design and programming
- 195 • Database validation and testing
- 196 • Edit check specification development and programming
- 197 • Data entry, review, coding, and cleaning
- 198 • Third party vendor management including vendors such as laboratory and eDiary
- 199 • Serious adverse event (SAE) reporting and reconciliation
- 200 • External data transfer and integration
- 201 • Quality control audits
- 202 • Database Lock

203 *b) Third Party Vendors*

204 Third-party vendors are subcontractors who are independent from the customer and
 205 supplier. They are individuals or organizations hired to perform services in obligation to
 206 and as a separate entity from the supplier. Common examples are the third party
 207 vendors that a CRO contracts for additional services such as interactive voice/web
 208 response system (IXRS), electronic diary (eDiary) for home visit/diaries, sites, central lab,
 209 specialty lab, material printing, face to face meeting organizers, monitors, patient travels,
 210 home visit nurse, PK/PD, immunogenicity, imaging, coding, and translations services.
 211 Typically, these vendors are selected shortly after the decision to conduct the study.
 212 Services to be subcontracted for a study should be decided prior to protocol finalization
 213 and before the first patient in (FPI). Different vendors may be desired for different
 214 functions, and preferred vendors may differ from organization to organization.

215 *c) Independent consultants/contractors*

216 Independent consultants (or contractors) are individuals who often do not have their
 217 own infrastructure or work for themselves. Any role on a study can be filled by an
 218 independent consultant. Independent consultants could be hired by the sponsor, a
 219 vendor, or a staffing firm working for a Sponsor or vendor and are usually hired for a
 220 specific project or program and for a short duration.

221 **7) Contracting Business Models**

222 The business model followed by a vendor can significantly affect the relationship between
 223 the vendor and the sponsor. The following are some of the more frequently encountered
 224 business models that could affect clinical data management.

225 *a) Transactional Model:*

226 The transactional model, in which a sponsor contracts vendors on a per-project or per-
 227 study basis, could be considered the traditional outsourcing model for clinical studies.
 228 The payment could be based on per unit (e.g., per hour or per unique CRF) or it could be

229 fixed cost per project based on the nature of the contract. Transactional relationships
230 may be more likely than other models to perform out-of-scope activities, resulting in cost
231 overrun.

232 *b) Strategic Partnerships:*

233 Strategic partnerships are usually formed between a sponsor and a vendor with
234 complementary resources and expertise. Strategic partnerships could be between a
235 sponsor and a company providing EDC services or other electronic tools for clinical
236 studies, or may be between a sponsor and a full-service CRO. Strategic partnerships may
237 also be formed to gain location-specific resources needed for studies that span multiple
238 countries or regions.

239 Before forming a strategic partnership, the sponsor should carefully evaluate the
240 potential partner. Ensure there are no significant differences between corporate
241 cultures, philosophies, or SOPs among sponsor, the strategic partner vendor, and other
242 vendors involved that could potentially lead to conflicts. Ensure that any identified issues
243 can be rectified to the satisfaction of all parties involved prior to the initiation of the
244 stated contract.

245 Some of the main reasons that sponsors opt for strategic partnerships are reduced cost,
246 improved efficiency in the use of internal staff, access to operational expertise; improved
247 quality, reduced contracting effort, reduced effort for provider selection, process
248 improvement, access to therapeutic expertise, access to experienced staff members, and
249 access to innovation and technology. While the benefits of a strategic partnership are
250 many, these relationships require investments of time and resources from both parties
251 to maximize the outcome. (Avoca 2016)

252 *c) Functional Service Provider (FSP) Models:*

253 In contrast to outsourcing all data management aspects of a study to a single CRO, an FSP
254 model may involve outsourcing only select activities. "Because project ownership
255 remains in-house, companies that use functional outsourcing may experience higher
256 levels of quality control yet have access to specific services at a lower overall cost.
257 Sponsor companies benefit from being able to ramp up and draw down resources
258 relative to their development activity levels without affecting their internal head count."
259 (Lucas 2008) Using an FSP model allows sponsors to focus on their core competencies
260 and outsource certain activities (such as CRF design or system validation) to niche
261 vendors, rather than needing to hire additional personnel or provide additional training
262 to existing personnel. An example of an FSP is a sponsor that hires a company to deliver
263 10 statistical programmers for the following year.

264 d) *Application Service Provider (ASP) Models:*

265 An ASP is a vendor that leases a software application to clients, and can involve contracts
266 that are for the duration of a study, for a set amount of time, or on a per-use basis, such
267 as per user, per study, per CRF, etc. Using an ASP shifts much of the responsibility to the
268 vendor for implementing, hosting, validating, maintaining, upgrading, and supporting the
269 software. However, because sponsors are ultimately responsible for data integrity and
270 quality, a risk-based approach should be used to determine the scope and depth of any
271 additional software testing and validation. Examples include EDC or electronic Patient
272 Reported Outcomes (ePRO) vendors. Some sponsors may oversee and manage these
273 vendors directly while others may delegate this responsibility to the CRO.

274 **8) Vendor Qualification, Initial Evaluation and Selection**

275 There is no “set in stone process” for vendor evaluation and selection; but what follows are
276 common and generally accepted processes. This approach may be modified depending on
277 whether the service provider is new or has past experience with the sponsor. There also may
278 be further modification based on the sponsor’s experience with the vendor and with the
279 service to be provided.
280



281 a) *Request for Information (RFI)*

282 The objective of RFI is to discuss the proposed strategy for vendor selection and gather
283 relevant information ahead of the resource evaluation and planning processes. It is a
284 best practice that study teams engage in early to begin a study-level sourcing strategy
285 and vendor identification. [VI] Based on the design of the study under consideration,
286 study specific needs and possible vendors can be identified. A template RFI that includes
287 specific services required for the study or program is a best practice. [VI] A sample RFI
288 template is available in Appendix B

- 289 Some of the general contents of the RFI include:
- 290 • Company information including history, financial stability trend, past or planned
 - 291 merger and acquisitions, and organizational structure
 - 292 • Indication that the potential vendor provides products and services relevant to the
 - 293 project
 - 294 • Number and types of sponsors or similar studies supported
 - 295 • Number of qualified personnel in key roles
 - 296 • Experience and expertise of current staff relevant to the project in the therapeutic
 - 297 area, study phase, or type of study, etc.
 - 298 • The vendor's geographic capabilities
 - 299 • The number of sponsors or studies currently supported by the available vendor staff
 - 300 • Capacity to take on the work to be contracted within the needed start-up time and
 - 301 for the project duration
 - 302 • Indication of services for which third-party vendors will be used
 - 303 • Availability for a pre-award survey / Quality Management System audit in the
 - 304 timeframe needed to cover the items indicated below
 - 305 • Indication of required accreditation in the vendor's field of work (e.g., lab
 - 306 certifications)
 - 307 • Indication of vendor's ability within the vendor's QMS to adapt to sponsor's SOPs if
 - 308 required
 - 309 • Indication of information system validation for regulated processes
 - 310 • Indication of information system change control processes
 - 311 • Indication that vendor can meet Service Level Agreement (SLA) requirements for the
 - 312 project
 - 313 • Indication of required physical and logical security practices; e.g., controlled facility
 - 314 access, server rooms, file rooms, information system authentication and role-based
 - 315 security, independent backup procedures, secure data transfer processes
 - 316 • Indication of disaster/contingency plan(s) to protect business operations
 - 317 • Indication of a vendor audit program
 - 318 • Description of vendor's experience with relevant business models
 - 319 • Description of the vendor's quality management system, including dates and scopes
 - 320 of ten most recent internal QMS audits
 - 321 • Dates and outcomes of previous regulatory inspections, as permitted
 - 322 • Description of the vendor's process for identifying and managing changes in scope
 - 323 • Description of the vendor's process for projecting, assigning, and managing project
 - 324 resources including the organization's succession planning process for project team
 - 325 members
 - 326 • Indication that vendor can meet any other project requirements such as an audit
 - 327 schedule, performance indicators, availability of documentation to regulators, etc.
 - 328 • References from previous customers

329 *b) Cross-Functional Team Discussion*

330 After obtaining information on different vendors, appropriate cross-functional teams
331 meet to review vendor's information to ensure that the services offered meet the needs
332 of the upcoming clinical study. Often at this stage a short list of the most attractive
333 vendors is developed. If all the functions are satisfied with the information, sponsor
334 requests the short-listed vendors for a proposal.

335 *c) Request for Proposal (RFP)*

336 A **request for proposal (RFP)** is a document shared by a company interested in
337 procurement of a service to potential suppliers requesting submission of business
338 proposals. Typically, the sponsor maintains a template for the RFP and bid grid that is
339 sent to the interested vendors with specific study information such as the protocol or the
340 protocol synopsis.

341 A **bid grid** is a tool provided by a purchaser (i.e., a Sponsor or delegate) to potential
342 vendors such as CROs usually along with an RFP. The bid grid categorizes and
343 standardizes the services or products being bid so that bids can be compared. The
344 categorization often informs contracting and expense reconciliation throughout the
345 contract. Most large pharmaceutical companies use bid grids. (Glass 2009) A bid grid may
346 have added columns indicating responsibility assignment or task ownership. In such
347 cases, the bid grid may be referred to as a roles and responsibilities (R&R) matrix.
348 Typically, the bid grid is maintained by a procurement or vendor management office,
349 though this may vary among organizations. (Hudgens and Hill 2010)

350 A bid grid serves two primary purposes:

- 351 • A bid grid captures the sponsor's predefined study-specific cost drivers
- 352 • A bid grid allows the outsourced partner to assign prices to specific tasks associated
353 with cost drivers

354 For all CDM cost drivers, a bid grid should include definitions of units, cost per unit, the
355 estimated number of units expected, and total anticipated costs for each row. The
356 structure of a bid grid should cover the scope of work and all tasks and units should be
357 clearly defined, meaningful, and measurable. In addition to specific CDM cost drivers, a
358 bid grid may also aggregate costs into high-level categories, such as all costs associated
359 with an investigator meeting or data cleaning.

360 Some high-level categories for pricing consideration include:

- 361 • CRF/eCRF design
- 362 • Database development (including edit check specifications)
- 363 • Data management plan development
- 364 • Data cleaning
- 365 • Management of local lab reference ranges
- 366 • Dictionary coding and up-versioning

- 367 • Management of external data
- 368 • SAE reconciliation
- 369 • Quality control audit(s)
- 370 • Data transfers
- 371 • Database finalization/lock

372 Some examples of CDM cost drivers include:

- 373 • Number of unique CRFs (paper or electronic)
- 374 • Number of total CRF pages (paper or electronic)
- 375 • Number of edit checks to be programmed
- 376 • Number of subjects to be enrolled
- 377 • Number of cleanup listings
- 378 • Number of external data sources (e.g., central labs, electronic diaries, etc.)
- 379 • Number of local labs
- 380 • Number of queries expected
- 381 • Number of terms to be encoded
- 382 • Number of SAEs to be reconciled
- 383 • Number of data review rounds
- 384 • Number and types of data transfers/integrations
- 385 • Number of unique status reports
- 386 • Frequency of status reports
- 387 • Frequency of teleconferences
- 388 • Number of interim database locks
- 389 • Number of Patients
- 390 • Patient Profiles reviews if utilized

391 *d) Evaluation of the RFP and Bid grid*

392 Once the vendor receives and completes the request, the bid will be submitted. Bid
393 defense, a face-to-face or teleconference meeting where vendor presents the contents
394 of the proposal is usually a part of this process. However, strategic partnership or
395 functional service provider relationships do not usually require a bid grid and bid defense
396 for each project.

397 Once the completed RFP / Bid grid is received, it is circulated to an appropriate cross-
398 functional team for function specific review. Senior personnel from each function usually
399 conduct the review. This functional assessment may include questions in a bid defense,
400 review of documentation provided by a prospective vendor such as the vendor quality
401 manual, SOPs, key team member qualifications, or example project plans. Some
402 assessments require a visit to vendor's location. On-site assessments, also called pre-
403 award surveys or pre-award audits may include the following:

- 404 • Review of the vendor's SOPs and work instructions to ensure soundness of processes
405 and proof of regulatory and industry standards compliance

- 406 • Confirmation of QMS audits indicated in the RFI
- 407 • Evaluation of the vendor's QC/QA processes
- 408 • Personnel qualification (through a review of, for example, curriculum vitae (CVs) of
- 409 company personnel, job descriptions, organizational charts, training plans and
- 410 documentation, etc.)
- 411 • Evidence of clearly defined project-specific training plans for new team members,
- 412 and adequate transition processes to address staffing changes that occur during a
- 413 study
- 414 • Sufficient staffing, including documented adherence to training and retraining plans
- 415 • Security of physical locations where services are provided (controlled facility access,
- 416 security of server rooms and file rooms, independent backup procedures, etc.)
- 417 • Physical conditions of server and file rooms (limited access, fireproof, controlled
- 418 temperature and humidity, etc.)
- 419 • Disaster/contingency plan(s) to protect business operations
- 420 • Evaluation of subcontractors and the vendor's management processes for those
- 421 subcontractors, if applicable

422 After relevant cost drivers have been shared with the vendor, the sponsor and vendor
423 should discuss variables that could affect pricing prior to the vendor completing the bid.
424 This discussion should include determination of which organization's SOPs will be
425 followed. If the sponsor's SOPs are to be followed, the sponsor will determine training
426 requirements for the vendor. Both parties should also consider which systems would be
427 used and if any standards or efficiencies can be applied to the project(s). During this
428 phase of the relationship, clear expectations should be agreed upon and documented.
429 Expectations to be discussed and documented should include the following:

- 430 • Communications (project status updates, escalation path, etc.)
- 431 • Quality (documents and data)
- 432 • Timelines and turnaround times
- 433 • Final deliverables

434 When working with a CRO, the final bid grid should be shared with the CRO parties in
435 charge of managing the study and study deliverables. Both parties (sponsor and CRO)
436 should review each task on the bid grid, line by line, to confirm understanding of the task
437 and confirm the responsibility and accountability (responsible party, approving party,
438 etc.) Each task should be explained to the CRO in sufficient detail prior to completion of
439 the bid so that both parties fully understand what is to be included and priced. See
440 Appendix C for an abbreviated sample bid grid.

441 **9) Approval**

442 At this stage, the RFP is finalized and work is awarded to vendors. Each applicable study
443 team member will review the budget and approve the scope of work generated by the

444 vendor. Once the official contract is signed, the vendor can begin work towards the
445 discussed study.

446 A Statement of Work (SOW) is comprised of legal language, which will define the high-level
447 services to be provided, deliverables and timeline for services being performed, the scope
448 with all the study specific details on services performed by the vendor, cost per service item,
449 and the signature of both parties

450 **10) Development of Contract and Scope of Work (SOW)**

451 Once potential vendors have been evaluated and vendor selections have been made, a
452 Contract as well as a Statement of the Scope of Work must be prepared and agreed upon by
453 the sponsor and the vendor. Many large companies have separate departments that handle
454 these details, but CDM personnel may be involved with these processes in some
455 organizations.

456 *a) Considerations for Sponsors, Vendors, and Data Managers*

457 The type of outsourcing business model to be used is a very important consideration in
458 preparing the contract and the scope of work. Because numerous variations can exist
459 between outsourcing relationships even when following the same outsourcing business
460 model, the contract and the scope of work for each vendor relationship may also have
461 unique variations.

462 When using models that involve more organizational integration, such as strategic
463 partnerships or an FSP relationship, both organizations should commit to several levels of
464 oversight (executive committees, operational committees, etc.) that focus on strategy
465 and implementation to ensure that the partnership is successful. Each level of oversight
466 should also be associated with a clear escalation path in case issues are not able to be
467 resolved at a particular level. Governance models should ensure long-term senior
468 management commitment from both sides.

469 For organizations using a transactional outsourcing business model, costs and scope of
470 work are typically based on certain assumptions. Because some of these assumptions
471 may be incorrect or based on changing information, the contract and scope of work
472 should include provisions detailing how changes will be handled. These provisions should
473 include a description of how changes to underlying assumptions may result in change
474 orders, as well as mitigation plans to resolve situations where the scope of work evolves
475 slowly over time (i.e., scope creep).

476 Although typically the responsibility of a legal department, CDM personnel should be
477 aware that contracts may include special clauses such as penalty clauses or bonus
478 clauses. These clauses are intended to give vendors incentives for exceeding
479 expectations, or disincentives for not meeting expectations.

480 b) *Common Components of a Contract*

481 Outsourcing relationships frequently start with a Master Services Agreement (MSA). The
482 MSA outlines the overarching agreement between the signing parties (e.g., Vendor and
483 Sponsor). Its purpose is to simplify future contracts. The MSA may contain details on
484 payment terms, indemnification, confidentiality, delivery requirements, intellectual
485 property rights, dispute resolutions, limitations, and work standards. In some cases, as is
486 often the case in a Strategic Partnership, a rate card or bid grid may be a part of the MSA.
487 Specific Scopes of Work (SOW) fall under the MSA. In most cases, this is where CDM
488 personnel will begin their involvement as MSAs are often negotiated by a legal team or
489 executive staff.

490 c) *Scope of Work*

491 In many cases the SOW looks similar to the Transfer of Regulatory Obligations (TORO) as
492 it details which party has responsibility for an activity; however, the SOW should contain
493 additional details for deliverables describing how the work will be done; resources
494 needed; assumptions made by the vendor; and costs for each deliverable. Costs may be
495 detailed in the SOW or in an attached Bid Grid.

496 It is important to review the SOW from multiple perspectives in order to make sure it is
497 complete. Changes to any aspect of the SOW usually result in a Change-In-Scope (CIS). A
498 CIS can take time to negotiate and can stop the progress of deliverables.

499 d) *Task Ownership Matrix*

500 A task ownership matrix identifies all tasks that may arise during execution of a clinical
501 study. It often goes a step beyond the TORO or SOW to include project team roles. The
502 matrix is intended to ensure all tasks are accounted for and to reduce the potential for
503 duplication of effort. Failure to develop a task ownership matrix, or developing one
504 poorly, can defeat the anticipated benefits that drove the parties to enter into an
505 agreement in the first place. For example, if both parties duplicate efforts with a task
506 because responsibility for the task is not clearly defined, duplicate costs are incurred and
507 the desired monetary savings of the relationship may never be realized. The matrix
508 should clearly identify the following four ownership responsibilities that occur with any
509 task or document:

- 510 • Who is *responsible* for this task or document (e.g., creation, revision, approval)
- 511 • Who is *accountable* for this task or document (e.g., the single individual held
512 accountable for the decision or task)
- 513 • Who is *consulted* for this task or document
- 514 • Who is *informed* for this task or document

515 The end result of a well-documented task ownership matrix, also known as a RACI
516 (responsible, accountable, consulted, informed) table, will be a better relationship
517 between the sponsor and vendor, as well as provide clear one-party accountability for

518 success or remediation of various tasks. Both parties should mutually agree upon the
 519 task ownership matrix prior to study startup. A sample RACI Chart Template is provided
 520 in the chapter entitled *Project Management for the Clinical Data Manager Appendix C*.

521 In addition to the bid grid, it is advised to consider both writing acceptance criteria and
 522 service level agreements within the contract. An example of acceptance criteria may
 523 mean a database with no open queries for a subset of subjects at a particular study
 524 milestone. Service level agreements are time-based agreed upon expectations for a
 525 service. An example of a service level agreement would be that all calls to the helpdesk
 526 would be returned within 24 hours.

527 **11) Vendor Oversight**

528 Organizational vendor oversight and management is a key part of an overall Quality
 529 Management System. How much effort your organization puts into a vendor oversight and
 530 management program will vary depending on your organization, the extent to which your
 531 organization outsources to vendors, the risk of the activity they are outsourcing, and the
 532 volume of work outsourced to a single vendor. This topic is also discussed in the *Assuring*
 533 *Data Quality Chapter* of the GCDMP.

534 It is important for your organization to have SOPs that address vendor selection and
 535 management. Your organization’s Quality Assurance Group likely has this. If not, it is
 536 recommended that you either create one or hire a qualified quality assurance or compliance
 537 company to do so.

538 An example of a risk based vendor oversight and management program is described below.
 539

Vendor Name	Experience with Vendor	Vendor Activity	Vendor Volume	Oversight
A+ CRO	New	Entire Clinical Trial	1 Phase 2 US trial	RFP, Bid defense, Vendor qualification by third party
Labs-R-Us	Used vendor for 4 studies over past 3 years with good results	All clinical labs for Phase 1-2 studies	Approx. 2 studies/year	Vendor audit by internal QA every other year

540

541 *a) Managing a vendor within the scope of a contract*

542 Your organization’s vendor governance program should be risk-based, meaning new
 543 vendors for a Phase 3 study that contribute data to the primary endpoint will most likely
 544 require more oversight than a frequent vendor partner that contributes exploratory data
 545 for a post-marketing study. According to ICH E6(R2), the project team should conduct the
 546 steps listed in the Quality Management Program beginning with Critical Process and Data
 547 Identification and moving through the subsequent steps in order. These are the

548 following: Risk Identification, Risk Evaluation, Risk Control, Risk Communication, Risk
549 Review and Risk Reporting. A detailed explanation for each of these steps can be found in
550 the *ICH E6(R2): Guideline for Good Clinical Practice* available from www.ich.org.

551 *b) Governance documents that may be used*

552 Several helpful documents may be used. Some common governance documents are:

553 *Service Level Agreement*

554 A Service Level Agreement, SLA, may be outlined in the MSA, SOW, or a separate
555 Vendor Governance Plan. It is commonly found in strategic partnership governance
556 plans. It is considered best practice to have SLAs defined for vendors with whom your
557 organization works frequently. An example of a CDM SLA is a mutually agreed upon
558 time from last query closed to database lock.

559 *Timelines, task, and deliverables list*

560 The clinical project manager will likely maintain a project timeline for high-level
561 deliverables such as First Patient First Visit (FPFV), site initiation dates, database lock,
562 etc.; however, there are many granular tasks and deliverables that must be tracked
563 that support these higher-level milestones. CDM staff may be asked to track vendor
564 deliverables such as data transfers, query resolution, data entered from data of
565 subject visit, etc. This is frequently referred to as a Deliverables List or they may be
566 sub-items in overall Project Management Plan using software such as Microsoft
567 Project or an equivalent document.

568 *Resource Management Plan*

569 A Resource Management plan will help you describe how many staff and at what
570 percent FTE each staff member is needed and for the duration that a deliverable
571 must be met. Such plans are often found in project management software or one can
572 be developed using Excel. An example Resource Management Plan to complete the
573 first draft DMP is below.

574

Task	Who	Estimated Hours	Target Date
Draft DMP	Lead CDM	8.0	01Dec2018
Internal QC DMP	Director, CDM	3.0	03Dec2018
Incorporate comments and send to sponsor	Lead CDM	4.0	05Dec2018

575

576 *Key Performance Indicators*

577 Key Performance Indicators (KPIs) are another frequently used tool to gauge the
578 health of a partnership. They are often collaboratively developed between parties. An

579 example of a KPI that effects vendor oversight is “Rate of Key Staff Turnover.” KPIs
 580 may be categorized by study stage such as Study Startup, Study Conduct, and Study
 581 Closeout since each stage has its own set of risks. This list should be modified as best
 582 fits your study, clinical program, or vendor partnership. Some example KPIs are listed
 583 below from the 2012 SCDM Annual Conference presentation entitled “Outsourcing
 584 DM: How to Get the Most Value out of a Partnership.” You will want to fine tune KPIs
 585 to fit your organization and clinical studies.
 586

Service	Service Level Description	Service Level Measurement	Minimum Service Level Expected by Sponsor	Target Service Level
Listing Review	All listings reviewed and queries generated	% of listings reviewed within 2 weeks of schedule	80%	95%
Queries Handling	Queries correctly generated	% of errors	90%	95%

587 Performance metrics such as SLAs and KPIs should be reviewed regularly with the
 588 vendor on a mutually agreed upon basis. An honest and collaborative review will
 589 provide insight for ways both parties can improve the overall effectiveness of their
 590 relationship.

591 *Communication Plan*

592 Appendix B in the chapter *Project Management for the Clinical Data Manager*
 593 provides an example Communication Plan Template. In addition to this plan, it is
 594 recommended that data management have regular biweekly (once every two weeks)
 595 or weekly meetings with a set agenda followed by meeting minutes to discuss
 596 upcoming milestones, plan resources, set priorities, and to build a respectful,
 597 collaborative relationship. Such meetings ensure risks to timeline or quality are
 598 identified early when such problems are more easily solved. In addition to Data
 599 Management meetings, one-to-one Sponsor/CRO meetings are very beneficial to
 600 plan and keep focus on the Data Management agenda.

601 The schedule for regular meetings should be specific to the protocol. For example, a
 602 study that is expected to be slow enrolling may have weekly data management
 603 meetings to oversee study start-up activities then reduce the schedule to monthly
 604 during the maintenance phase. It is recommended that status updates and study
 605 metrics be reviewed at these meetings.

606 Occasionally, unfortunate events such as missed deadlines or a high degree of errors
 607 requires escalation. According to the Glossary of Communication Terminology
 608 escalation is “The process which details how conflicts and issues will be passed up the
 609 management chain for resolution as well as the timeframe to achieve resolution.
 610 ”(Project Management Documents, 2019) It is recommended that an Escalation Plan
 611 be developed for any vendor relationship where there is a significant amount of work

612 (i.e., Strategic Partnerships; Functional Service Provider relationships). Development
 613 and approval of the plan early in the relationship is important before any escalation
 614 issues need to be addressed. An escalation plan should be based on impact of the
 615 issue at hand with the goal of addressing low impact issues within the first level of
 616 escalation. The sample Communication Escalation Process below was obtained via
 617 www.ProjectManagementDocs.com, within the Communications Management Plan
 618 Template.
 619

Priority	Definition	Decision Authority	Timeframe for Resolution
Priority 1	Major impact to project or business operations. If not resolved quickly there will be a significant adverse impact to revenue and/or schedule.	Vice President or higher	Within 4 hours
Priority 2	Medium impact to project or business operations that may result in some adverse impact to revenue and/or schedule.	Project Sponsor	Within one business day
Priority 3	Slight impact that may cause some minor scheduling difficulties with the project but no impact to business operations or revenue.	Project Manager	Within two business days
Priority 4	Insignificant impact to project but there may be a better solution.	Project Manager	Work continues and any recommendations are submitted via the project change control process

620 Unfortunately, there are times when a decision is made to terminate a vendor
 621 relationship. Again, it is recommended to develop and approve an exit plan for any
 622 vendor relationship where there is a significant amount of work at the start of the
 623 relationship. Doing so will mitigate risks.

624 Detailing the criteria for terminating a relationship is best outlined at the beginning of
 625 the relationship so that there is a mutual understanding.

626 The process for termination of work is usually detailed in the Master Services
 627 Agreement (MSA) between the vendor and sponsor. Clinical Data Managers should
 628 familiarize themselves with this section of the MSA; however, the exit plan duties for
 629 closing out the scope of work may fall to the data manager. In that event, an example
 630 Exit Plan for data management activities using the RACI model is suggested below.
 631

Task	Responsible	Accountable	Consulted	Informed
Communication to Stakeholders	Project Manager	VP or Executive	DM Lead	Study Team members
Acknowledgement of Receipt for Stop Work	Project Manager	VP or Executive	DM Lead	Study Team members
Financial reconciliation of	DM Lead (for DM activities)	Project Manager	DM Study Team	DM Study Team
Archival of Work Completed	DM Lead (for DM activities)	Project Manager	DM Study Team	DM Study Team

632

633 c) *What to do when you have to oversee a vendor you did not select?*

634 Ideally, the data manager will be involved in the development of the SOW; however,
635 many times CDM staff is not involved in the development of the SOW but often ends up
636 with the responsibility of managing the vendors who contribute to the development of
637 the clinical database. If this is your situation, the first thing to do is to thoroughly review
638 and understand the SOW. If you notice any aspect of the SOW that could lead to
639 miscommunication, missed timelines, or incorrect assumptions, it is best to alert the
640 project manager and senior management within data management as soon as possible.
641 Dealing with potential problems sooner rather than later is usually less expensive and
642 less of a headache.

643 d) *Inheriting vendor oversight mid-stream in a project*

644 Sometimes a data manager will inherit vendor oversight in the middle of a project. This
645 may happen for any number of reasons. The primary project manager may realize that
646 vendor oversight needs more care and attention to ensure the integrity of the trial's data
647 and safety of the subjects, or perhaps the previous data manager was reassigned or left
648 the organization. In any case, the steps to get up to speed are the same and are outlined
649 below:

- 650 • Read the contract with the vendor. Know the assumptions that drive the vendor's
651 budget and the components for each deliverable.
- 652 • Familiarize yourself with the protocol and any associated study plans where the
653 vendor plays a part.
- 654 • Do not assume that because vendor oversight was not originally scoped in study
655 plans that it is not needed. Decide for yourself using your own quick assessment
656 of risk identification and assessment taken from the ICH E6(R2) guideline.
- 657 • Make a plan and communicate your plan to the rest of the study team.
- 658 • What you do from there will depend on project team decisions.

659 Whatever the outcome of the project team, responsibility for vendor oversight
660 should not be considered as an afterthought. If an activity is important enough to
661 outsource, it is important enough to make sure it is done correctly.

662 **12) Recommended Standard Operating Procedures**

663 a) Vendor Qualification

664 b) Vendor Oversight

665 **13) Appendices:**

- 666 • Appendix A. Vendor List Template
- 667 • Appendix B. Request for Information (RFI) Template
- 668 • Appendix C. Bid Grid Template
- 669 • Request for Proposal (RFP) Template (Included as an Appendix to the EDC Chapter
670 titled Selecting an EDC System)
- 671 • RACI Matrix template (Included as an Appendix in the current GCDMP)
- 672

673 **14) Revision History**

Date	Revision description
December 2019	Complete revision

674
675

676 **Regulations, Guidance, and Standards**

- 677 1. Title 21 CFR Part 312 Responsibilities of Sponsors and Investigators (Delegation of
678 Sponsor Responsibilities)
- 679 2. Food and Drug Administration, E6(R2) Good Clinical Practice: Integrated Addendum
680 to ICH E6(R1) Guidance for Industry, March 2018. Available from
681 <https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm464506.pdf>
682
- 683 3. International Organization for Standardization. (2015). ASQ/ANSI/ISO 9001:2015
684 Quality management systems requirements. In International Organization for
685 Standardization (5th ed.). Geneva, Switzerland: ISO.
- 686 4. Software Engineering Institute (SEI), CMMI V2.0 Development Model, 28 March,
687 2018. Available from the Software Engineering Institute,
688 [https://cmmiinstitute.com/resources?searchtext=Tags%3A%20MDD%20Quick%20Reference%20Guide,%20Quick%20Reference%20Guide,%20V2.0&searchmode=anywordProject Management Institute](https://cmmiinstitute.com/resources?searchtext=Tags%3A%20MDD%20Quick%20Reference%20Guide,%20Quick%20Reference%20Guide,%20V2.0&searchmode=anywordProject%20Management%20Institute). (2013). Chapter 12: Project procurement
689 management. In Project management institute: A guide to the project management
690 body of knowledge (5th ed., pp. 355-390). Newtown Square, PA.
691
- 692 5. Title 21 CFR Part 820 Quality System Regulation
- 693

- 694 6. Center for Drug Evaluation and Research, Food and Drug Administration, Guidance
695 for Industry Q10 Pharmaceutical Quality System, April 2009. Available from
696 <https://www.fda.gov/downloads/Drugs/.../Guidances/ucm073517.pdf>
697 7. Food and Drug Administration, Guidance for Industry Q9 Quality Risk Management,
698 June 2006, available from
699 <https://www.fda.gov/downloads/Drugs/Guidances/ucm073511.pdf>
700 8. Food and Drug Administration, Guidance for Industry Q8(R2) Pharmaceutical
701 Development, November 2009. Available from
702 <https://www.fda.gov/downloads/drugs/guidances/ucm073507.pdf>
703 9. Food and Drug Administration, E6(R2) Good Clinical Practice, Step 2 version, June 11,
704 2015. Available from
705 <https://www.fda.gov/downloads/Drugs/Guidances/UCM464506.pdf>
706 10. International Organization for Standardization. (2009). ISO 31000:2009 Risk
707 management – Principles and guidelines. In International Organization for
708 Standardization (3rd ed.). Geneva, Switzerland: ISO.
709 11. International Organization for Standardization. (2009). ISO 9004:2009 Managing for
710 the sustained success of an organization: A quality management approach. In
711 International Organization for Standardization (3rd ed.). Geneva, Switzerland: ISO.
712 12. International Organization for Standardization. (2009). ISO/IEC 31010:2009 Risk
713 management – Risk assessment techniques. In International Organization for
714 Standardization (1ST ed.). Geneva, Switzerland: ISO.
715 13. International Organization for Standardization. (2015). ISO 9000:2015 Quality
716 management systems fundamentals and vocabulary. In International Organization for
717 Standardization (4th ed.). Geneva, Switzerland: ISO.
718 14. Communications Management Plan page of *Project Management Docs*
719 (projectmanagementdocs.com). Accessed December 11, 2019. Available from
720 [https://www.projectmanagementdocs.com/template/project-](https://www.projectmanagementdocs.com/template/project-planning/communications-management-plan/#axzz67rSXzdbe)
721 [planning/communications-management-plan/#axzz67rSXzdbe](https://www.projectmanagementdocs.com/template/project-planning/communications-management-plan/#axzz67rSXzdbe)
722

723 Referenced in Text

- 724 1. (Avoca DIA presentation 2016) ([http://theavocagroup.com/wp-](http://theavocagroup.com/wp-content/uploads/2017/04/2016-Avoca-Industry-Survey-Report.pdf)
725 [content/uploads/2017/04/2016-Avoca-Industry-Survey-Report.pdf](http://theavocagroup.com/wp-content/uploads/2017/04/2016-Avoca-Industry-Survey-Report.pdf)).
726 2. Lucas K.M., Steps to Functional Service Provider Success: Outsourcing fundamentals
727 for this pick-and-choose model so that both sponsors and service providers win. Aug
728 01, 2008 Available from: [http://www.appliedclinicaltrials.com/steps-functional-](http://www.appliedclinicaltrials.com/steps-functional-service-provider-success)
729 [service-provider-success](http://www.appliedclinicaltrials.com/steps-functional-service-provider-success)
730 3. Glass H.E., An outsourcing necessity. Applied Clinical Trials, 2009. Available from
731 <http://www.appliedclinicaltrials.com/outsourcing-necessity-0>
732 4. Hudgens S. and Hill R., Managing vendor relationships. Pharmaceutical outsourcing,
733 January/February 2010 Volume 11, Issue 1. Available from
734 [https://www.pharmoutsourcing.com/Featured-Articles/37566-Managing-Vendor-](https://www.pharmoutsourcing.com/Featured-Articles/37566-Managing-Vendor-Relationships/)
735 [Relationships/](https://www.pharmoutsourcing.com/Featured-Articles/37566-Managing-Vendor-Relationships/)

736

737 **For Further Reading**

- 738 1. Buchholz, K. (2000). Working with contract research organizations. In R. K. Rondel, S.
739 A. Varley, & C. F. Webb (Eds.), *Clinical Data Management* (pp. 293-305). John Wiley &
740 Sons, LTD.
- 741 2. Getz, K., & Zuckerman, R. (2008, May 30). Clinical research outsourcing: Moving from
742 transactional to strategic partnership-based outsourcing. Retrieved from
743 ContractPharma: [http://www.contractpharma.com/issues/2008-](http://www.contractpharma.com/issues/2008-06/view_features/clinical-research-outsourcing)
744 [06/view_features/clinical-research-outsourcing](http://www.contractpharma.com/issues/2008-06/view_features/clinical-research-outsourcing)
- 745 3. Outsourcing DM: How to get the most value out of a partnership. (2012). SCDM
746

747

748 Appendix A: Vendor List Template

749

Vendor Name	Vendor Address	Vendor Contact Name	Vendor Title	Vendor Phone Number	Vendor Email	Services Provided Previously Provided	Services Approved for use by QA	Date of Last Qualification Audit	Auditor for Last Qualification Audit	Date of Requalification Needed
Just Right Labs	xxxx	xxxx	xxxx	xxxx	xxxx	Clinical Lab Services	Clinical Lab Services; PK Lab Services	15-Feb-18	Internal QA	15-Feb-20

750

751

752

753 Appendix B: Sample Request for Information (RFI)

Company Information
1. Provide a brief description of the company's history, including length of time in the industry, origins of the company, mission statement and vision.
2. Provide an organizational chart. Include position and number of employees in each department (senior management, technical support, user support, technical and client service managers, sales and marketing, development, recruiting, quality assurance, training, etc.).
3. Describe quality assurance processes and roles. Is the quality assurance organization independent of the operational organization?
4. Describe the current level of company funding.
5. Describe the company's pricing model.
6. Describe the quality management system adopted by the company.
7. Describe the validation/change control processes of the computerized systems.
8. Describe results of prior audits.
9. Describe quality oversight on contractors (if applicable).
10. If applicable, provide the results of previous regulatory inspections.

Products/Services
1. Describe the evolution of your product or service.
2. How many clients are currently using your product or service?
3. Describe your user support services (IT, helpdesk, IVRS, etc.).
4. Describe the company's interpretation of 21 CFR 11 and how your product is in compliance with this regulation.
5. Can your company produce Clinical Data Interchange Standards Consortium (CDISC) compliant data? If so, which model or models?
6. Describe the company's involvement and specific recommendations for user training. Differentiate between clinical studies with a few sites and those with a large number of sites, if appropriate.
7. What other products or services do you offer?

Experience
1. How many studies has your company supported in the past ____ years?
2. What is the largest clinical study completed to date with respect to number of sites, number of subjects? What lessons did you learn?
3. What are some of the qualities of your company from a human resource perspective? (e.g., What is your rate of turnover? What percentage of your employees are contract versus permanent? What are your training procedures?)
3. What user feedback have you solicited or received from study site personnel or clients about your product or services? How was the feedback addressed?
4. Provide references.
5. Provide CVs and training plans for the proposed personnel.

754

755

756 Appendix C: Sample Bid Grid

CRO SERVICES	Unit	Cost / Unit	Estimated Number of Units	Item Cost
DATA MANAGEMENT				
Project Management	Month			\$0.00
CRF Creation	Per Unique Page			\$0.00
CRF Guidelines	Per Unique Page			\$0.00
Create Data Management Plan	Plan			\$0.00
Design Database	Per Unique Page			\$0.00
Program Derived Fields	Per Unique Page			\$0.00
Program Data Edit Specifications (to include number of edit checks to be developed)	Per Edit check/Per Unique Page			\$0.00
Query Rate (queries X pages X subjects)	Page			\$0.00
Line Listing Review (for Safety, Sponsor, etc)	Listing			\$0.00
Data Management Review	Page			\$0.00
Data Coding	Code			\$0.00
Provide Coding Dictionaries	Dictionary			\$0.00
SAE Reconciliation	SAE			\$0.00
Lab Normal Maintenance	Lab Site			\$0.00
External Data Loads	Load			\$0.00
QC Audit	Page			\$0.00
Database Lock	Lock			\$0.00
Database Transfer(s)	Transfer			\$0.00
TOTAL				\$0.00

757